Tagged with UK,

Europe Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the future of European pharma post-Brexit, with the UK diverging from the rest of the continent in regulatory terms and the launch of the European Commission’s Pharmaceutical Strategy for Europe.   After four…

Saudi Arabia Following on from our list of the overall top 10 companies in the Saudi Arabian pharma market, here PharmaBoardroom highlights some of the top domestic companies in the USD 8.2 billion Saudi pharma market, many of which are now well-established and carving out international footprints.   Tabuk Pharmaceuticals Founded in…

UK Graeme Duncan, CEO of ADVANZ PHARMA, highlights how the specialty generics firm has revitalized its operations since 2018 both culturally and operationally and introduces its growing specialty pharma portfolio. Duncan also touches on ADVANZ’s response to the COVID-19 pandemic, key learnings for the future, and calls for a reappraisal of…

UK When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left behind in terms of alignment with the world’s top regulatory bodies. Perhaps cognizant of this, the UK regulatory agency for…

UK The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as its third largest export destination. However, with the Japanese government having previously expressed concern about uncertainties arising from the Brexit…

Saudi Arabia The top 10 pharma companies in Saudi Arabia ranked by sales value in USD millions MAT Q1 2019. These top 10 corporations account for 50 percent of total sales in the USD 8.2 billion Saudi pharma market. Global giants Pfizer, Sanofi, and Novartis make up the top three spots, but…

UK US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research Centre’ by 2025.   Having announced that the hub would be built in 2017, one year after the UK’s vote…

UK Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national innovation forwards.   With the upheaval of recent months, businesses up and down the UK have been forced to adapt…

Roundup Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access developments.   Coronavirus leading to ICU drug shortages In the UK the coronavirus pandemic is leading to shortages of drugs…

Coronavirus The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19); an unprecedented agreement that shows the scale of the challenge facing the global biopharmaceutical industry and possibly provides the world’s…

UK With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life science investment destinations and multinational pharma firms including Novartis are already taking note.   “Tangible Opportunity” In February 2020, the…

UK Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get Brexit Done”.   The UK now enters an 11-month transition period to disentangle political and economic ties from a single…